Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY ESTABLISHES COMPLIANT U.S. PEPTIDE ACCESS WITH TELEHEALTH AND PRESCRIPTION INFRASTRUCTURE PARTNERSHIP

The Precision Peptide Company Inc. has signed an agreement with a United States-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfilment and delivery of the company's peptide products.

Highlights

• Signed an agreement with a United States-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfilment and delivery of the company's peptide products;
• Builds on the company's recently announced 503A compounding agreement, under which all peptides -- including BPC-157 -- are to be 100-per-cent compounded in the United States;
• Partner platform is trusted by more than 100 telehealth brands and is designed to align with U.S. legal, HIPAA and pharmacy regulations;
• Connects licensed provider networks across all 50 U.S. states with prescription and pharmacy fulfilment workflows;
• Supports a compliant, nationwide U.S. infrastructure for prescription-based peptide access ahead of anticipated U.S. regulatory developments.

This news follows the company's recently announced compounding agreement with a U.S.-based 503A sterile compounding pharmacy, under which all of the company's peptides -- including BPC-157 -- are to be 100-per-cent compounded in the United States (see news release dated June 2, 2026). Today's announcement builds on that foundation by adding the prescription and telehealth infrastructure that connects licensed prescribers, patients and pharmacy fulfilment within a single compliant pathway.

The partner operates a telehealth platform that is trusted by more than 100 telehealth brands and connects licensed provider networks across all 50 U.S. states with prescription workflows and pharmacy fulfilment. The platform is designed to align with U.S. legal, HIPAA and pharmacy regulations.

Pratap Sandhu, chief executive officer of The Precision Peptide Company, commented: "We have secured 100-per-cent U.S. compounding for our peptides, and this agreement adds the prescription and telehealth infrastructure to deliver them effectively. Together, these two pieces position the company to pursue compliant, prescription-based access to our products, subject to applicable regulatory developments. We are putting this infrastructure in place ahead of the PCAC's review of BPC-157, the company is ready to move as regulatory clarity develops."

As previously disclosed, the FDA has referred several peptides -- including BPC-157 -- to the pharmacy compounding advisory committee (PCAC), which is scheduled to review these substances at a public meeting on July 23, 2026.

With its U.S.-based 503A compounding agreement and prescription and telehealth infrastructure now in place, the company has built out a pathway for prescription-based peptide access in advance of the review.

About The Precision Peptide Company Inc.

The Precision Peptide Company is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.